Asset Management One Co. Ltd. Raises Position in TESARO Inc (TSRO)

Asset Management One Co. Ltd. lifted its stake in TESARO Inc (NASDAQ:TSRO) by 4.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 63,660 shares of the biopharmaceutical company’s stock after purchasing an additional 2,690 shares during the period. Asset Management One Co. Ltd. owned 0.12% of TESARO worth $8,178,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in TESARO by 11.6% in the third quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 23,739 shares of the biopharmaceutical company’s stock valued at $3,065,000 after acquiring an additional 2,476 shares during the last quarter. AMP Capital Investors Ltd boosted its stake in TESARO by 108.9% in the third quarter. AMP Capital Investors Ltd now owns 15,152 shares of the biopharmaceutical company’s stock valued at $1,955,000 after acquiring an additional 7,900 shares during the last quarter. Artisan Partners Limited Partnership bought a new position in TESARO in the third quarter valued at approximately $16,627,000. KBC Group NV boosted its position in shares of TESARO by 10.9% during the third quarter. KBC Group NV now owns 5,606 shares of the biopharmaceutical company’s stock worth $724,000 after purchasing an additional 553 shares in the last quarter. Finally, Dai Ichi Life Insurance Company Ltd boosted its position in shares of TESARO by 158.9% during the third quarter. Dai Ichi Life Insurance Company Ltd now owns 22,375 shares of the biopharmaceutical company’s stock worth $2,889,000 after purchasing an additional 13,732 shares in the last quarter.

Shares of TESARO Inc (NASDAQ TSRO) opened at $80.58 on Monday. TESARO Inc has a 52-week low of $77.20 and a 52-week high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.69. The business had revenue of $142.77 million for the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm’s revenue was up 740.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.72) EPS. research analysts forecast that TESARO Inc will post -8.17 EPS for the current year.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Martin H. Jr. Huber sold 592 shares of TESARO stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the sale, the senior vice president now owns 6,943 shares in the company, valued at $823,439.80. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.

A number of brokerages have recently weighed in on TSRO. Robert W. Baird reissued a “neutral” rating and set a $125.00 price target on shares of TESARO in a research report on Monday, October 2nd. BidaskClub raised shares of TESARO from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. SunTrust Banks reissued a “buy” rating and set a $235.00 price target on shares of TESARO in a research report on Sunday, August 20th. Jefferies Group reissued a “hold” rating and set a $124.00 price target on shares of TESARO in a research report on Friday, November 3rd. Finally, Wells Fargo & Company reissued an “outperform” rating on shares of TESARO in a research report on Sunday, August 20th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $159.39.

COPYRIGHT VIOLATION NOTICE: “Asset Management One Co. Ltd. Raises Position in TESARO Inc (TSRO)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/12/18/asset-management-one-co-ltd-raises-position-in-tesaro-inc-tsro.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

What are top analysts saying about TESARO? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit